Inventiva S.A. (IVA) Form 6-K — May 26, 2026
Inventiva S.A. reported Q1 2026 financial results, disclosing cash and cash equivalents of €75.0 million and short-term deposits of €121.5 million as of March 31, 2026. This represents a decrease from €99.3 million in cash and €131.6 million in deposits at year-end 2025, driven by planned operating expenses for its lanifibranor development program. The company recognized no revenue in the first quarter, consistent with its clinical-stage status and prior quarter performance.
Key figures
- Revenue
- 0
- Total Assets
- 121.5 million EUR
- Cash Position
- 75.0 million EUR
- Cash Runway Base
- mid-Q1 2027
- Prior Cash Position
- 99.3 million EUR
- Short Term Deposits
- 121.5 million EUR
- Cash Runway With Warrants
- mid-Q3 2027
- Prior Short Term Deposits
- 131.6 million EUR
- Potential Warrant Proceeds
- 116.0 million EUR
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.